Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kuan, Gandelman"'
Publikováno v:
Clinical Ophthalmology (Auckland, N.Z.)
Anthony S Basile,1 Matthew M Hutmacher,2 Kenneth G Kowalski,2 Kuan Y Gandelman,3 Dana J Nickens1 1Clinical Pharmacology, Specialty Care Business Unit, Pfizer Inc, San Diego, CA, USA; 2Ann Arbor Pharmacometrics Group, Ann Arbor, MI, USA; 3Clinical Pha
Autor:
Michael J. Lamson, Joanne Salageanu, Kyle Matschke, Bimal Malhotra, Kuan Gandelman, Candace Bramson
Publikováno v:
Clinical Pharmacology in Drug Development. 4:370-376
WHAT IS KNOWN AND OBJECTIVE ALO-02 is being developed as an abuse-deterrent formulation of extended-release oxycodone hydrochloride with naltrexone hydrochloride sequestered in the core of pellets contained in capsules. The primary objective of this
Autor:
Kyle Matschke, Michael J. Lamson, Joanne Salageanu, Candace Bramson, Kuan Gandelman, Bimal Malhotra
Publikováno v:
Clinical Pharmacology in Drug Development. 4:361-369
ALO-02 capsules (ALO-02) contain pellets that consist of extended-release oxycodone that surrounds sequestered naltrexone. The primary objective was to characterize the pharmacokinetics (PK) of oxycodone following single- and multiple-dose oral admin
Autor:
Frank Jen, Bimal Malhotra, Marc R. Gastonguay, Kuan Gandelman, Ahmed El-Tahtawy, William Knebel
Publikováno v:
The Journal of Clinical Pharmacology. 53:505-516
The population pharmacokinetics (PPK) of atorvastatin and its principal active metabolite, o-hydroxyatorvastatin, were described in 6-17 years old pediatric hypercholesterolemia patients with a 2-compartment model for both parent and metabolite. Info
Publikováno v:
American Journal of Therapeutics. 19:164-173
The aim of the present study was to determine whether there is a differing pattern of systemic exposure to atorvastatin in Asian versus Caucasian subjects by comparison of data obtained from completed pharmacokinetic studies. Pharmacokinetic data wer
Autor:
Maurice Dickins, Kuan Gandelman, Bimal Malhotra, Gregory Duczynski, Zhanna Jumadilova, Christine Alvey, Xiaoxi Li
Publikováno v:
British Journal of Clinical Pharmacology. 72:263-269
AIMS To assess the effects of fluconazole, a moderate CYP3A4 inhibitor, on the pharmacokinetics (PK) and safety/tolerability of fesoterodine.
Publikováno v:
British Journal of Clinical Pharmacology. 72:257-262
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Drug–drug interactions with warfarin are common with potentially harmful consequences. Preclinical in vitro studies suggest that fesoterodine or 5-hydroxymethyl tolterodine are not likely to affect warfa
Publikováno v:
Pediatric Cardiology
This study aimed to assess the efficacy and tolerability of atorvastatin in Tanner stage (TS) 1 patients ages 6 to 10 years and TS ≥ 2 patients ages 10 to18 years with genetically confirmed heterozygous familial hypercholesterolemia (HeFH) and a lo
Autor:
Ilise Lombardo, Mark Versavel, Paul Glue, Robert R. LaBadie, Sheldon H. Preskorn, Jeffrey Alderman, Kuan Gandelman
Publikováno v:
The Journal of Clinical Psychiatry. 70:58-62
Background Food is known to increase the bioavailability of ziprasidone. Therefore, we evaluated the effects of meals of differing caloric and fat content on steady-state ziprasidone exposure in a stable, treated group of subjects with DSM-IV diagnos
Autor:
Kuan, Gandelman, Michael, Lamson, Joanne, Salageanu, Candace, Bramson, Kyle, Matschke, Bimal, Malhotra
Publikováno v:
Clinical pharmacology in drug development. 4(5)
ALO-02 is being developed as an abuse-deterrent formulation of extended-release oxycodone hydrochloride with naltrexone hydrochloride sequestered in the core of pellets contained in capsules. The primary objective of this study was to assess the effe